Caremo Recognized as a "2024 Jiangsu Potential Unicorn Enterprise"

Recently, the Productivity Centre of Jiangsu Province announced the 2024 assessment results for Jiangsu’s Unicorn and Gazelle Enterprises, with Caremo securing a spot on the prestigious "2024 Jiangsu Potential Unicorn Enterprise" list.

This recognition follows a comprehensive evaluation of the company’s technological innovation, market performance, and investment value. Being consecutively selected as a Jiangsu Potential Unicorn Enterprise in both 2023 and 2024 underscores Caremo’s robust R&D capabilities, technological innovation capacity, rapid growth trajectory, and significant potential for future expansion. It also reflects strong confidence in the company’s long-term prospects.

As a Potential Unicorn Enterprise, Caremo Pharmaceutical remains committed to advancing cutting-edge drug R&D technologies, fostering deeper integration of innovation and industrial collaboration, and accelerating drug development timelines while reducing costs and improving efficiency. Staying true to its mission—“Born for Health, Empowered for Innovation”—the company aims to establish itself as a benchmark for high-tech, high-growth, and high-value enterprises. Through these efforts, Caremo Pharmaceutical will continue to propel the advancement of China’s pharmaceutical industry and deliver transformative solutions for global healthcare challenges.